Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulation… Read more
Canntab Therapeutics Limited (CTABF) - Total Assets
Latest total assets as of February 2023: $953.54K USD
Based on the latest financial reports, Canntab Therapeutics Limited (CTABF) holds total assets worth $953.54K USD as of February 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Canntab Therapeutics Limited - Total Assets Trend (2011–2022)
This chart illustrates how Canntab Therapeutics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Canntab Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (May 2022)
Canntab Therapeutics Limited's total assets of $953.54K consist of 51.4% current assets and 48.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.2% |
| Accounts Receivable | $209.72K | 7.4% |
| Inventory | $489.26K | 17.2% |
| Property, Plant & Equipment | $1.08 Million | 38.0% |
| Intangible Assets | $303.82K | 10.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2022)
This chart illustrates how Canntab Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Canntab Therapeutics Limited's current assets represent 51.4% of total assets in 2022, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2022, down from 99.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 38.0% of total assets.
Canntab Therapeutics Limited Competitors by Total Assets
Key competitors of Canntab Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Canntab Therapeutics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Canntab Therapeutics Limited generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Canntab Therapeutics Limited is currently not profitable relative to its asset base.
Canntab Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 1.20 | 14.24 |
| Quick Ratio | 0.02 | 0.64 | 14.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.78 Million | $ 543.65K | $ 4.15 Million |
Canntab Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Canntab Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.74 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -55.2% |
| Total Assets | $2.85 Million |
| Market Capitalization | $3.87K USD |
Valuation Analysis
Below Book Valuation: The market values Canntab Therapeutics Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Canntab Therapeutics Limited's assets decreased by 55.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Canntab Therapeutics Limited (2011–2022)
The table below shows the annual total assets of Canntab Therapeutics Limited from 2011 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-05-31 | $2.85 Million | -55.16% |
| 2021-05-31 | $6.36 Million | +15.46% |
| 2020-05-31 | $5.51 Million | +112.42% |
| 2019-05-31 | $2.59 Million | -45.39% |
| 2018-05-31 | $4.75 Million | +47060.46% |
| 2017-12-31 | $10.07K | -99.11% |
| 2017-05-31 | $1.14 Million | +6565.54% |
| 2016-12-31 | $17.06K | -98.73% |
| 2016-05-31 | $1.34 Million | +376.02% |
| 2015-05-31 | $282.14K | -17.48% |
| 2014-05-31 | $341.93K | +70.70% |
| 2013-05-31 | $200.31K | -70.52% |
| 2012-05-31 | $679.48K | -20.01% |
| 2011-05-31 | $849.48K | -- |